EGFR and non-small cell lung carcinoma: Two anilinoquinazoline EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, were approved for use in unselected patients with NSCLC in the 2nd and 3rd line setting after failure of first line platinum-based chemotherapy in 2003 and 2004, respectively in the United States [21] and some patients were noted to have major and sometimes durable responses [22].